Assess · Manage · Command
A gap-analysis and risk-management system for emerging biopharma — company intelligence, launch-readiness tooling, and a fractional expert network, built for the run from Series A funding to commercial launch.
Series A–C dollars get spent redoing what an earlier, reasonable decision locked in — and the gaps surface as audit findings and board questions, at the worst possible moment.
Each function picks its own path and its own vendors, by referral and under pressure — and nobody owns the whole picture.
The person holding the launch plan leaves, or the org restructures mid-flight — and the context walks out with them.
The commercial roles that would own this arrive late, and a full-time executive hire costs more than most Series B/C budgets can absorb before there's revenue to justify it.
Commercial readiness gets rebuilt from zero at each company, under deadline pressure, instead of starting from a system that already knows the shape of the problem.
A 79-item baseline framework across 10 categories — extensible per company — so the plan lives in the system, not in one person's head.
Company Intelligence and the Vendor Marketplace build the map of your landscape and the vendors who solve for it.
Maturity Assessments, Third Party Assessments, and the Launch Readiness Index turn that map into a number you can track.
AI Insights, the Risk Register, and the Launch Readiness Tracker rank what's urgent — prioritized by legal and regulatory exposure, weighed against your runway and your PDUFA date, not just the lowest score.
The Expert Advisor Network puts a vetted, fractional executive on the gap once it has an owner and a next step.
Every workstream between funding and launch, in the modules that make up Source, Score, Surface, and Staff above.
A living directory of Series A–C biopharma companies, built on public SEC, clinical trial, and FDA data — pipeline, funding, and regulatory milestones in one place.
A structured checklist spanning every commercial launch workstream, from serialization to government pricing, tracked against your own timeline.
Score your organization's readiness across dozens of launch-critical workstreams, and track how that score moves as you close gaps.
Claude reads your assessment answers and surfaces the gaps most likely to block a commercial launch — prioritized by legal and regulatory exposure, not just the lowest scores.
Every launch-readiness category plotted by maturity score against open risk exposure, so the gaps most worth acting on next are visible at a glance, not buried in an average.
A living record of identified risks, owners, mitigation plans, and remediation status — fed directly by AI Insights and your own team.
Send cybersecurity, AI-governance, and data-handling questionnaires to vendors and partners, and review what comes back — just a link, no email infrastructure required.
A directory of vendors mapped to the exact launch workstream they solve for, so a vendor search never starts from a blank page.
A vetted bench of fractional executives — commercial, regulatory, IT, HR, and finance — matched to the launch workstream where you need help.
Curated biopharma conferences and events relevant to your stage and therapeutic area.
Executive and team calendars for the recurring meetings and deadlines that matter, filtered to what your role and team give you access to.
Once a gap has an owner and a next step, our advisory network connects you to vetted, fractional-ready executives across the functions a launch actually needs — engaged for the workstream in front of you, not a long-term hire.
Functions covered
Log in to pick up your company's launch readiness, or get in touch if you're not on the platform yet.